

## **Third Party Payment Declaration**

EU/EEA MSC	Czech Republic
Sponsor	Regeneron Pharmaceuticals, Inc.
Sponsor's trial code	R1979-HM-2298
EU CT number	2022-502660-20-00
Study Title	A Phase 3, Open-label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)
Short description of application: (e.g. iCTA Part I and/or Part II, SM Part I and/or Part II, additional MSC)	

We, ICON Clinical Research Ltd. hereby confirm that the fees incurred by the Member State Concerned in connection with the review and evaluation of the Clinical Trial Application under the Clinical Trial Regulation (EU) No 536/2014 referenced above, will be paid as per the applicable national law, by the payer mentioned below.

## **Invoice details**

Name of payer company	ICON Clinical Research Ltd
Street	South County Business Park, Leopardstown
City and zip code	Dublin 18
Country	Ireland
VAT number, as applicable	IE 820 1978R
Payment reference number	0456/0558
(Please state the at the invoice)	
E-mail: (Preferred delivery)	SubmissionsCR@iconplc.com

Invoices for the fees and expenses related to the review and evaluation of above-mentioned application should be sent to the recipient below:

Name of payer company	ICON Clinical Research s.r.o.
Contact person	Mgr. Viera Kučerová
Street	V Parku 2335/20
City and zip code	148 00 Praha 4 – Chodov
Country	Czech Republic
Payment reference number	0456/0558
(Please state the at the invoice)	
E-mail: ( <i>Preferred delivery</i> )	SubmissionsCR@iconplc.com